Literature DB >> 15793144

Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient.

Sébastien Hantz1, Detlef Michel, Anne-Marie Fillet, Vincent Guigonis, Gaël Champier, Marie-Christine Mazeron, Albert Bensman, François Denis, Thomas Mertens, Axelle Dehee, Sophie Alain.   

Abstract

We describe the emergence of a new ganciclovir resistance mutation in the UL97 gene of human cytomegalovirus, deletion of codon 601, after valaciclovir and short-term ganciclovir therapy following kidney transplantation. Its role in ganciclovir resistance was supported by decreased ganciclovir phosphorylation in a recombinant vaccinia virus system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793144      PMCID: PMC1068598          DOI: 10.1128/AAC.49.4.1580-1583.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir.

Authors:  S Chou; C L Meichsner
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

2.  Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.

Authors:  Sunwen Chou; Rachel H Waldemer; Anne E Senters; Kevin S Michels; George W Kemble; Richard C Miner; W Lawrence Drew
Journal:  J Infect Dis       Date:  2001-12-17       Impact factor: 5.226

3.  Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system.

Authors:  Fausto Baldanti; Detlef Michel; Lavinia Simoncini; Maria Heuschmid; Albert Zimmermann; Rosalba Minisini; Peter Schaarschmidt; Thomas Schmid; Giuseppe Gerna; Thomas Mertens
Journal:  Antiviral Res       Date:  2002-04       Impact factor: 5.970

4.  Emergence of multiple drug-resistant human cytomegalovirus variants in 2 patients with human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy.

Authors:  Fausto Baldanti; Stefania Paolucci; Aldo Parisi; Luca Meroni; Giuseppe Gerna
Journal:  Clin Infect Dis       Date:  2002-03-19       Impact factor: 9.079

5.  Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

Authors:  D Lowance; H H Neumayer; C M Legendre; J P Squifflet; J Kovarik; P J Brennan; D Norman; R Mendez; M R Keating; G L Coggon; A Crisp; I C Lee
Journal:  N Engl J Med       Date:  1999-05-13       Impact factor: 91.245

6.  Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

Authors:  Ajit P Limaye
Journal:  Clin Infect Dis       Date:  2002-09-10       Impact factor: 9.079

7.  Efficacy and safety of lowering immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study.

Authors:  Dany Anglicheau; Alexandre Lautrette; Catherine Scieux; Martin Flamant; Frédéric Morinet; Christophe Legendre
Journal:  Nephrol Dial Transplant       Date:  2003-08       Impact factor: 5.992

Review 8.  Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs.

Authors:  Fausto Baldanti; Nell Lurain; Giuseppe Gerna
Journal:  Hum Immunol       Date:  2004-05       Impact factor: 2.850

9.  Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.

Authors:  Alexandra Ducancelle; Stéphanie Belloc; Sophie Alain; Catherine Scieux; Marion Malphettes; Françoise Petit; Jean-Claude Brouet; Marie-José Sanson Le Pors; Marie-Christine Mazeron
Journal:  J Clin Virol       Date:  2004-04       Impact factor: 3.168

10.  Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients.

Authors:  Nell S Lurain; Sangeeta M Bhorade; Kenneth J Pursell; Robin K Avery; Vijay V Yeldandi; Carlos M Isada; Emmanuel S Robert; Debra J Kohn; Max Q Arens; Edward R Garrity; Alan J Taege; Martin G Mullen; Kathleen M Todd; James W Bremer; Belinda Yen-Lieberman
Journal:  J Infect Dis       Date:  2002-08-28       Impact factor: 5.226

View more
  4 in total

1.  Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.

Authors:  Sunwen Chou; Ronald J Ercolani; Adam L Vanarsdall
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

Review 2.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 3.  Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients.

Authors:  Katharina Göhring; Klaus Hamprecht; Gerhard Jahn
Journal:  Comput Struct Biotechnol J       Date:  2015-02-10       Impact factor: 7.271

4.  Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed Patients.

Authors:  Hossein Keyvani; Sedigheh Taghinezhad Saroukalaei; Amir Hossein Mohseni
Journal:  Jundishapur J Microbiol       Date:  2016-05-29       Impact factor: 0.747

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.